![]() |
Name |
(5E,9Z)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one
|
Molecular Formula | C18H30O | |
IUPAC Name* |
(5E,9Z)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one
|
|
SMILES |
CC(=CCC/C(=C\CC/C(=C/CCC(=O)C)/C)/C)C
|
|
InChI |
InChI=1S/C18H30O/c1-15(2)9-6-10-16(3)11-7-12-17(4)13-8-14-18(5)19/h9,11,13H,6-8,10,12,14H2,1-5H3/b16-11-,17-13+
|
|
InChIKey |
LTUMRKDLVGQMJU-HSVQFRAPSA-N
|
|
Synonyms |
(5E,9Z)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one; Farnesyl acetone, (5e,9Z)-; 3KCT4WMT7E; 3953-35-3; (5E,9Z)-farnesyl acetone; FEMA No. 3442, (5e,9Z)-; 5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (E,Z)-; 5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (5E,9Z)-; 6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one; UNII-3KCT4WMT7E; farnesylaceton; SCHEMBL14236986; CHEBI:176714; ZINC14822753; Q27257403
|
|
CAS | 3953-35-3 | |
PubChem CID | 1711944 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 262.4 | ALogp: | 5.6 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 17.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 19 | QED Weighted: | 0.473 |
Caco-2 Permeability: | -4.65 | MDCK Permeability: | 0.00002410 |
Pgp-inhibitor: | 0.349 | Pgp-substrate: | 0.023 |
Human Intestinal Absorption (HIA): | 0.051 | 20% Bioavailability (F20%): | 0.991 |
30% Bioavailability (F30%): | 0.948 |
Blood-Brain-Barrier Penetration (BBB): | 0.541 | Plasma Protein Binding (PPB): | 99.38% |
Volume Distribution (VD): | 2.817 | Fu: | 1.17% |
CYP1A2-inhibitor: | 0.535 | CYP1A2-substrate: | 0.502 |
CYP2C19-inhibitor: | 0.31 | CYP2C19-substrate: | 0.686 |
CYP2C9-inhibitor: | 0.35 | CYP2C9-substrate: | 0.959 |
CYP2D6-inhibitor: | 0.22 | CYP2D6-substrate: | 0.83 |
CYP3A4-inhibitor: | 0.192 | CYP3A4-substrate: | 0.166 |
Clearance (CL): | 6.941 | Half-life (T1/2): | 0.755 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.903 |
Drug-inuced Liver Injury (DILI): | 0.021 | AMES Toxicity: | 0.001 |
Rat Oral Acute Toxicity: | 0.002 | Maximum Recommended Daily Dose: | 0.077 |
Skin Sensitization: | 0.943 | Carcinogencity: | 0.045 |
Eye Corrosion: | 0.669 | Eye Irritation: | 0.933 |
Respiratory Toxicity: | 0.008 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001466 | ![]() |
1.000 | D09XWD | ![]() |
0.785 | ||
ENC001464 | ![]() |
0.729 | D05XQE | ![]() |
0.632 | ||
ENC001467 | ![]() |
0.725 | D03VFL | ![]() |
0.483 | ||
ENC001462 | ![]() |
0.679 | D01ZUA | ![]() |
0.266 | ||
ENC001096 | ![]() |
0.679 | D0M1PQ | ![]() |
0.242 | ||
ENC001716 | ![]() |
0.646 | D06BLQ | ![]() |
0.202 | ||
ENC002413 | ![]() |
0.621 | D0Q7ZQ | ![]() |
0.198 | ||
ENC001717 | ![]() |
0.621 | D0X7XG | ![]() |
0.190 | ||
ENC001427 | ![]() |
0.529 | D0UE9X | ![]() |
0.174 | ||
ENC003133 | ![]() |
0.512 | D0Q6DX | ![]() |
0.169 |